denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease
Hematology Disease Topics & Pathways:
Antibody Therapy, Clinical Practice (Health Services and Quality), Diseases, Immune Disorders, Immunodeficiency, Treatment Considerations, Biological therapies, Infusion, Monoclonal Antibody Therapy
Session: ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease
Hematology Disease Topics & Pathways:
Antibody Therapy, Clinical Practice (Health Services and Quality), Diseases, Immune Disorders, Immunodeficiency, Treatment Considerations, Biological therapies, Infusion, Monoclonal Antibody Therapy
Saturday, December 7, 2024, 9:30 AM-10:45 AM
Disclosures: Cunningham-Rundles: Pharming: Membership on an entity's Board of Directors or advisory committees; X4: Membership on an entity's Board of Directors or advisory committees; Otsuka: Other: DSMB; Grifols: Speakers Bureau; Grifols: Other: DSMB.
See more of: ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease
See more of: Education Program
See more of: Education Program